Where Can You Check the AOD-9604 Papers?
Each numbered mark beside a claim leads to one paper below.
How do the numbered marks help you?
The papers below support the claims about AOD-9604. Marks such as [1] and [2] point to one numbered paper. Each entry gives the writers, journal, year, and a link when one is available. Those details let you check a claim yourself.
The list covers animals, lab-grown cells, and people. It also includes the rabbit knee study and sport drug tests. A mouse paper can explain a mouse result. Only a study in people can tell you what happened to people.
Each claim was checked against the paper named by its mark. The list tells you where the claim came from. It doesn't turn animal work into human proof. For a health choice, your doctor can help you weigh the human results.
What will you find in the paper list?
The first entry covers weight and fat in mice. Later papers cover people, rabbit knees, safety, and sport tests. Each entry gives its full title and link.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. ↗
- Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449. ↗
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278. ↗
- Bornstein J, Ng FM, Heng D, Wong KP. Metabolic actions of pituitary growth hormone. I. Inhibition of acetyl CoA carboxylase by human growth hormone and a carboxyl terminal part sequence acting through a second messenger. Acta Endocrinologica (Copenhagen). 1983;103(4):479-486. ↗
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. ↗
- More MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism. 2014;4(3):64-77. ↗
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science. 2015;45(4):426-432. ↗
- Ng FM, et al. Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes. Biochemistry and Molecular Biology International. 1993;31(4):631-639. ↗
- Ng FM, et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology. 2000;25(3):287-298. ↗
- Adan RA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clinical Pharmacology and Therapeutics. 2010;87(6):748-751. ↗
- Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:66-83. ↗
- Vanhee C, Moens G, Deconinck E, De Beer JO. Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. Drug Testing and Analysis. 2014;6:964-968. ↗
- Schänzer W, Thevis M. Human sports drug testing by mass spectrometry. Mass Spectrometry Reviews. 2017;36:16-46. ↗
- AOD-9604 (Metabolic Pharmaceuticals). Drug development profile. Current Opinion in Investigational Drugs. 2004;5(4):437-441. ↗
- Halford JC. Obesity drugs in clinical development. Current Opinion in Investigational Drugs. 2006;7(4):312-318. ↗